Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Phase 2 Study of Sintilimab, Pegaspargase Combined with Gemcitabine and Oxaliplatin (P-P-GEMOX) Regimen for Newly Diagnosed Extranodal NK/T-Cell Lymphoma

NCT06824883 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT06824883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06824883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Phase 2 Study of Sintilimab, Pegaspargase Combined with Gemcitabine and Oxaliplatin (P-P-GEMOX) Regimen for Newly Diagnosed Extranodal NK/T-Cell Lymphoma
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 20, 2024
Completion date
May 20, 2027
Enrollment
49 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk/t-cell lymphoma